NCT01374321View on ClinicalTrials.gov

Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Acute Myocardial Infarctus
Interventions
DRUG

TRO40303

6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)

DRUG

Placebo

single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)

Trial Locations (11)

4011

Larsen, Stavanger

4956

Oslo University Hospital, Oslo

5000

Odense University Hospital, Odense

9000

Aarhus University Hospital, Aalborg

13005

Hôpital La Timone, Marseille

75015

Hôpital Européen Georges Pompidou, Paris

94010

Hôpital Henri Mondor, Créteil

Unknown

Hôpital Nord Marseille, Marseille

NO-5021

Haukeland University Hospital, Bergen

SE-221 85

Skane University Hospital, Lund

SE-171 76

Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Hoffmann-La Roche

INDUSTRY

NCT01374321 - Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter